INTRODUCTION
Hepatitis B virus (HBV) infection remains a major public health problem affecting 350 million people worldwide despite important achievements in prevention and treatment. Mother-to-infant transmission is crucial in the maintenance of the hepatitis B surface antigen (HBsAg) chronic carrier reservoir because the age of infection is the most determining factor in developing chronicity. If infection occurs after vertical transmission, there is a 95% risk of the patient developing a chronic infection.
1,2 In the absence of vaccination, neonates born to HBsAg 1 or hepatitis B e antigen-positive (HBeAg 1 ) mothers have a 70-90% risk of infection, while neonates born to HBsAg 1 /HBeAg 2 mothers have a 10-30% risk of infection. 3, 4 Although the exact mechanism of vertical transmission is still unclear, it has been postulated that passage of HBV virions or infected PBMCs through the placenta or during the perinatal period is involved. [5] [6] [7] Identified risk factors for the development of infection include high maternal perinatal viremia and the transplacental passage of HBeAg. 8, 9 Both infected and uninfected infants have been shown to encounter HBeAg in utero, but exposure to hepatitis B core antigen (HBcAg), which would indicate possible exposure to virions, has not been documented in babies of either HBeAg 1 or HBeAg 2 mothers. 8, 10 Prevention of mother-to-infant transmission has been largely achieved by the administration of passive hepatitis B immunoglobulin and active immunoprophylaxis to all neonates born to carrier mothers. However, the added benefit of passive immunoprophylaxis in newborns of HBsAg 1 /HBeAg 2 carrier mothers has recently been questioned. Currently, the recommended schedules for the prevention of vertical transmission vary significantly among countries and depend mainly on the HBeAg prevalence.
The establishment of chronicity after vertical transmission has been mainly attributed to the physiologically immature immune system of the neonate. However, the hepatitis B vaccine induces a vigorous antibody response early in most infants that correlates with the protective efficacy of vaccination against mother-to-infant transmission.
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This protection is achieved by the production of HBsAg-specific T helper 1 (Th1) and Th2 cells. A few reports have shown that uninfected infants born to HBsAg 1 /HBeAg 2 mothers have impaired HBsAg-specific T-cell responses that correlate with immunization failure and the presence of HBV DNA in PBMCs. 7, 12 The aim of the present study was to investigate the T-cell immune responses of uninfected neonates born to HBsAg 1 /HBeAg 2 mothers against HBV antigens and vaccination. Th1 and Th2 cytokine production was assessed following HBcAg and HBsAg stimulation in infants at birth, 1 and 6 months of age. Because HBcAg is not included in the vaccine, any HBcAg-induced responses could be due to a previous encounter with HBV virions or viral derivatives. Furthermore, adaptive immune responses to HBsAg were compared to that of control infants to investigate whether potential exposure influences the response to vaccination.
MATERIALS AND METHODS

Subjects and vaccination scheme
All subjects selected for this study were born to HBsAg 1 /HBeAg 2 , HCV-and HIV-negative mothers who had no clinical or laboratory signs of active hepatitis B at the time of delivery and had not received any antiviral treatment during pregnancy. All newborns were born at term (37-41 gestation weeks) and birth weight was greater than 2500 g. In accordance with national recommendations, subjects received one dose of 200 IU of hepatitis B immunoglobulin and their first hepatitis B vaccine (Engerix; GlaxoSmithKline Biologicals, Rixensart, Belgium) within 24 h of birth. The hepatitis B vaccination was completed by another two doses of monovalent vaccine at 1 and 6 months of age. Blood samples from neonates were collected by peripheral vein puncture at birth (before the administration of passive-active immunoprophylaxis); at 1 month of age (before the second vaccination dose); and at 6 months of age (10-14 days after the last vaccination dose). Because infants were not examined at all three time points, data were analyzed as a cross-sectional study (Supplementary Figure 1) . All vaccinated neonates were re-examined at 7 months of age for hepatitis B surface antibody (anti-HBs) quantification.
The control group consisted of infants born to HBV-, HCV-and HIV-negative mothers who were followed in our outpatient clinic. In accordance with national guidelines, they received three doses of hepatitis B vaccine using combined vaccine (Infarix-Hexa; GlaxoSmithKline Biologicals) at 2, 4 and 6 months of age. Blood sampling in control infants took place at the same time points as the subject infants and was coupled with routine hematologic work-ups.
This research protocol was approved by the Ethics Committees of both Alexandra Maternity General Hospital and the Second Pediatric Clinic of the University of Athens (P&A Kyriakou Children's Hospital). All mothers included in the study signed informed consent forms.
Serological HBV markers and HBV DNA Hepatitis B serological markers and HBV DNA levels were determined in all mothers enrolled in the study on the day of delivery. Plasma HBsAg and HBeAg were assayed by ELISA Kits (AXSYM; Abbot Laboratories, Abbott Park, IL, USA). HBV DNA was quantified using an ultrasensitive in-house real-time detection PCR (RTD-PCR) assay. The HBV DNA was extracted from 0.5 ml serum using the QIAamp UltraSens Virus Kit (QIAGEN Inc., Valencia, CA, USA) and eluted in 60 ml elution buffer. The RTD-PCR was carried out in the LightCycler II apparatus using RTD-PCR conditions described previously. 13 The 95% HBV DNA detection end point of the assay was 22 IU/ml or 60 copies/ml. 14 
Hepatitis B antigens
A purified preparation of yeast-derived recombinant HBsAg without vaccine additives (GlaxoSmithKline Biologicals) and two purified, truncated, Escherichia coli-derived recombinant hepatitis B core antigens (rHBcAgs) corresponding to amino acid sequences 1-127 (rHBcAg127) and 1-145 (rHBcAg145) (Rhein Biotech Dynavax, Düsseldorf, Germany) were used. Both antigen and peptide variants were .95% pure. The peptide concentration for the stimulation of HBsAg-and HBcAg-specific T cells was optimized at 10 mg/ml (data not shown) and was used throughout the study.
In vitro lymphocyte responses to HBV antigens PBMCs were isolated by Ficoll density gradient centrifugation (Sigma, St Louis, MO, USA) and resuspended in complete RPMI-1640 medium (Cambrex Bio Sciences Walkersville, Inc., Walkersville, MD, USA) supplemented with 2 mM L-glutamine (Cambrex Bio Sciences Walkersville, Inc.), 1% non-essential amino acids (Cambrex Bio Sciences Walkersville, Inc.), 10% human AB serum (Sigma) and antibiotics penicillin (100 U/ml) and streptomycin (100 mg/ml) (both from Cambrex Bio Sciences Walkersville, Inc.). PBMCs were seeded at 1310 6 cells/ml in a 48-well culture plate (Corning Inc., Corning, NY, USA) with 10 mg/ml phytohemagglutinin mitogen (PHA-L; Sigma), 10 mg/ml recombinant HBsAg, 10 mg/ml rHBcAg127 and 10 mg/ml rHBcAg145 (in the same well) or medium alone. Following a 72-h incubation at 37 uC in a humidified CO 2 (5%) incubator, culture supernatants were collected and stored at 220 uC until use.
Cytokine quantification
The levels of IFN-c were determined by sandwich ELISA using a commercial kit (BD Biosciences, San Diego, CA, USA) according to the manufacturer's instructions. The detection limit of the assay was 4 pg/ml.
The levels of IL-2, IL-5, IL-6 and IL-10 in the supernatants of cultured PBMCs were assessed by flow cytometry using the human cytometric bead array as per the manufacturer's instructions (BD Biosciences, San Jose, CA, USA). Briefly, capture bead populations with distinct fluorescence intensities were coated with cytokinespecific capture antibodies. Volumes of 50 ml of the recombinant standards or supernatants, 50 ml of phycoerythrin-conjugated detection antibodies and 50 ml of the mixed-bead population were mixed and incubated for 3 h. The newly formed sandwich complexes were then washed, and the sample data were acquired on a FACSCalibur with BD Cytometric Bead Array Software (BD Biosciences). Cytokine concentrations were quantified using FACSDiva and FCAP Array software.
Statistical analysis
Differences in numeric variables between groups were analyzed by the non-parametric Mann-Whitney test with two-tailed P values. Results were expressed as mean6standard error of the mean, and a P value of ,0.05 was considered statistically significant. Statistical calculations were performed using the GraphPad Prism Software (version 3) program.
RESULTS
Population description
The study population consisted of 23 neonatal subjects born to HBsAg 1 /HBeAg 2 mothers who were followed during their first 7 months of life for a total of 46 observations (Supplementary Figure 1) . Neonates of 24 healthy mothers served as controls. Perinatal viremia was detected in 54.3% of carrier mothers with a median viral load of 3.663.4 log 10 copies/ml on the day of delivery. All infants remained HBsAg 2 and had anti-HBs antibody levels above 10 IU/l at the age of 7 months.
Cytokine responses against HBV antigens Spontaneous and mitogen (PHA)-induced cytokine secretion was comparable among subjects and controls at all ages (Figure 1a) .
Immune
Cytokine responses against PHA, HBcAg and HBsAg were similar between neonates born to viremic and non-viremic mothers as well as to control neonates (P.0.005). IFN-c production following HBcAg stimulation in the subject group was higher than that in the control group, but this difference was not significant (P.0.05). Although controls were born to HBVnegative mothers, low but detectable IFN-c secretion in HBcAgtreated cells was seen in eight out of 24 individuals; the magnitude of these responses was below 20 pg/ml (Figure 1b) . This phenomenon was attributed to bacterial contamination because HBcAg was E. coli derived and was .95% pure. To avoid false-positive results, only subjects that responded with .20 pg/ml IFN-c production were considered to have positive HBcAg-specific responses. Figure 2 shows IFN-c production from the subjects that responded to HBcAg. When these responses were compared to those of age-matched controls, differences were statistically significant at birth, 1 and 6 months of age (P50.0039, P50.0022 and P50.0129, respectively). The responses to HBcAg were not correlated with maternal viremia in the subject group.
IFN-c concentrations following HBsAg stimulation were below 25 pg/ml, except for one 6-month-old control subject who responded with 400 pg/ml. There were no significant differences between subjects and controls at all ages examined (Figure 1c) .
Secretion of IL-2, IL-5, IL-6 and IL-10 was assessed at 6 months of age and after HBsAg stimulation in eight neonates, six of which were born to viremic mothers (4.264 log 10 vc/ml) and five controls (Figure 3) . A significantly increased production of IL-2 was observed in the subject group compared to the control group (P50.02). IL-5 and IL-6 secretions were also higher in the subject group, but this difference was not statistically significant (P50.17 and P50.09, respectively). Cytokine production was not associated with the maternal levels of HBV DNA, and IL-10 secretion was comparably low in both groups (P50.94).
DISCUSSION
T helper cells can be categorized as Th1 or Th2 cells according to the cytokines they produce. Th1 cells are characterized by IL-2, IFN-c and transforming growth factor-b production, whereas Th2 cells secrete mainly IL-4, IL-5 and IL-6. Both Th1 and Th2 responses against HBV antigens are required for successful immunoprophylaxis or clearance of the virus. The high incidence of infection and the development of chronic infection in infants born to HBsAg-carrier mothers have been attributed to viral antigen-specific unresponsiveness of both Th1 and Th2 cells. 7, 15, 16 In neonates born to HBsAg 1 /HBeAg 1 mothers, immune tolerance is further induced by transplacental passage of HBeAg that can result in specific tolerance of T helper cells to both HBeAg and HBcAg because these two antigens are crossreactive. 6, 17 However, intrauterine infection and immunoprophylactic failure have also been reported in infants of HBsAg 1 /HBeAg 2 mothers. 7, 18 Most studies of neonatal T-cell responses against HBV have focused on the immune responses elicited by HBsAg in vaccinated healthy infants. 15, 16, 19 In the present study, all subjects were born to HBsAg 1 / HBeAg 2 mothers, of which 54.3% had detectable HBV viremia on the day of delivery. All subject neonates remained uninfected postimmunoprophylaxis and responded to vaccination, with anti-HBs Immune responses in newborns of HBV-positive mothers L Koumbi et al 456 titers above 10 IU/l. 20 To evaluate the effect of the HBV-infected maternal environment on neonatal immune responses, we assessed HBcAginduced IFN-c production at birth, 1 and 6 months of age. Although there was detectable cytokine production in the control group, the magnitude of these responses was significantly higher in almost onethird (30.4%) of the patients (Figure 1b) . Because we used an E. coliderived recombinant HBcAg preparation that was .95% pure to stimulate the PBMCs throughout the study, a ,0.5 mg/ml concentration of bacterial protein may have contributed to the low but detectable IFN-c production in the control group. Although not using a control antigen derived from E. coli limits the study, the magnitude of the HBcAg-induced responses in the patients was increased by up to 20-fold, and we used a threshold point to avoid false-positive results (Figures 1b and 2 ). In addition, differences in antigen-induced cytokine production did not correlate to spontaneous or mitogen-stimulated cell responses ( Figure 1a) ; therefore, cytokine secretion was not caused by a non-specific reaction or by generalized immune dysfunction.
To explain these observed specific IFN-c responses, one could postulate that neonates were exposed to virions in utero or during the delivery. In the newborn subjects that elicited HBcAg-specific T-cell responses at birth, viral encounter must have taken place in utero, because if this encounter was during birth there could not have been sufficient time for the development of antigen specific immune responses. However, neonates that developed responses at 1 month of age or older might have been exposed at birth. The fact that HBcAgspecific IFN-c secretion in newborn subjects was not associated with maternal perinatal HBV DNA levels could be due to the small number of subjects analysed. One may wonder why these neonates did not get infected, because they could not have been protected by perinatal administration of immunoprophylaxis. The absence of infection in this group was most likely due to low maternal viral load (3.663.4 log 10 copies/ml), the absence of HBeAg and/or the efficiency of innate and adaptive immune responses. The finding that HBcAg-induced IFN-c production increases with age and that proportionally more neonates responded at 1 or 6 months of age may be due to the physiologic functional T-cell and dendritic cell maturational process during infancy. Alternatively, the finding may be explained by the higher probability that encounter with virions or viral derivatives took place during the delivery rather than in utero.
The responses to vaccination were assessed by measuring cytokine secretion following HBsAg stimulation. At birth, although subjects were unvaccinated, HBsAg-specific IFN-c production was observed in four neonates in the subject group, which did not correlate with mitogen responses or with maternal viremia. Interestingly, these four neonates also had HBcAg-specific IFN-c production. This finding further suggests the possibility that these newborns were exposed to virions or viral derivatives in utero.
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HBV DNA presence in the serum and PBMCs of uninfected infants born to HBsAg 1 /HBeAg 2 mothers has been shown in previous reports. 7, 18 Interestingly, PBMCs have been found to be persistently positive for HBV DNA during the first year of life but the serum is negative for HBV DNA and HBsAg. Similarly to HBV, specific T-cell responses have been detected in uninfected but in-utero-exposed infants born to HIV-positive mothers during the first year of life. 22, 23 However, it is not clear whether antigen-specific responses observed in neonates are due to encounter with free particles. HBV-specific T-cell responses could have been induced by maternal anti-idiotypic antibodies crossing the placenta 24 or by the passage of small quantities of HBV virions and free HBV proteins that are unable to establish a productive infection but could prime HBV-specific T cells, as seen in other infections. To evaluate the influence of HBV maternal infection on neonatal vaccination outcomes, HBsAg-induced Th1 and Th2 cytokine production was assessed 10 to 14 days after the completion of the vaccination course. 19 IFN-c production in 6-month-old subjects was as low as the age-matched controls. The level of IL-2 was significantly higher in subjects than in controls. IL-2 plays a crucial role in the development of anti-HBs antibody responses: it further induces IFN-c secretion and promotes the proliferation and differentiation of B lymphocytes. Levels of the Th2 cytokines IL-5 and IL-6 were also higher in the subject group, although not to a statistically significant level, and IL-10 was comparably low in both groups. Cytokine responses were not correlated with anti-HBs antibody titers or maternal viremia. Although all neonates responded to vaccination, the production of IL-2, IL-5 and IL-6 following HBsAg stimulation in the control group as well as IFN-c and IL-10 production in both groups resembled what would be expected in non-responder neonates. 19 Therefore, other immunological pathways are involved in the development of anti-HBs antibody production in neonatal life. Jafarzadeh et al. have shown that HBsAg-specific Th1 and Th2 production in vaccinated neonates varies significantly among individuals and does not correlate with anti-HBs antibody production. In our present study, the differences observed in HBsAg responses between subjects and controls may be attributed to the different vaccination courses they received. Neonates from the subject group received active and passive immunoprophylaxis at birth and some may have encountered HBsAg before birth.
The main weaknesses of this study are the small number of subjects and the cross-sectional design. Although parents were asked to bring neonates back to the clinic for follow-up, not all children were examined at all three time points. All control infants were examined at one time point during their vaccination course and another one after its completion during routine examination in our outpatient department.
Taken together, our results indicate that even in the absence of maternal HBeAg and in low maternal viremia, one-third of uninfected neonates show evidence of specific T helper cell responses. These responses could be due to intrauterine and/or perinatal encounter with virions and/or vital particles. This encounter, however, does not impair neonatal T-cell responses to vaccination. Additional studies from our group and other reports have shown that circulating and cord blood dendritic cells from uninfected neonates of carrier mothers are numerically and functionally efficient to present HBsAg. 25, 26 The presence of maternal viremia does not impair neonatal immune responses to vaccination and is not correlated with the development of viral antigen-specific cytokine production. This correlation would have been an oversimplified explanation to a much more complex issue because a single time point measurement of HBV viremia cannot predict viral antigen encounter. More information about the immune responses during mother-to-infant transmission is critical to the understanding of HBV infection and vaccination in neonatal life.
Note: Supplementary information is available on the Cellular & Molecular Immunology website (http://www.nature.com/cmi/).
